Bristol Myers Squibb Co.

Bristol Myers Squibb Co. has shown strong stock performance, with notable gains over various time frames. Key financial metrics indicate solid growth in net sales and operating profit, alongside a significant operating cash flow. The company maintains a robust market capitalization while navigating the competitive pharmaceutical landscape.

Bristol Myers Squibb Co. faced a significant stock decline, contrasting with the S&P 500's modest gain. Over the past month, the company has shown a decline, although it reported healthy long-term growth metrics, including a notable increase in net sales and operating profit, reflecting solid financial fundamentals.

Bristol Myers Squibb Co. saw a significant stock decline today, contrasting with the broader market. Despite recent challenges, the company reported strong long-term growth metrics, including notable increases in net sales and operating profit. The stock is currently trading at a discount compared to its peers.

Bristol Myers Squibb Co. has recently revised its evaluation amid changing market conditions. The stock price is currently $58.11, with a notable performance range over the past year. While it has outperformed the S&P 500 year-to-date, longer-term returns have lagged behind the index.

Bristol Myers Squibb Co. has recently revised its market evaluation, with its stock priced at $58.95. The company has experienced volatility over the past year, with a high of $62.88 and a low of $42.52. Year-to-date, it has outperformed the S&P 500, showing a return of 9.29%.

Bristol Myers Squibb Co. has recently revised its evaluation amid changing market conditions. The stock is priced at $61.10, reflecting a year of significant performance fluctuations. While the company has outperformed the S&P 500 in the short term, longer-term challenges remain evident in its competitive positioning.

Bristol Myers Squibb Co. saw a notable increase in stock performance on October 30, 2025, reaching an intraday high. The company has demonstrated resilience with a solid annual net sales growth rate and strong operating cash flow, alongside high institutional ownership, indicating investor confidence.

Bristol Myers Squibb Co. has reached a new 52-week low, reflecting significant stock volatility. With a market capitalization of approximately USD 127,940 million, the company has a P/E ratio of 15.00 and a high dividend yield of 80.34%. Its return on equity stands at 51.19%, while the debt-to-equity ratio is 2.05.

Bristol Myers Squibb Co. has seen a significant rise in stock performance, reaching an intraday high and outperforming the S&P 500 in one-day metrics. Despite a challenging year-to-date performance, the company reported strong operational metrics and high institutional ownership, reflecting investor confidence.

Bristol Myers Squibb Co. has recently revised its evaluation amid fluctuating market conditions. The stock, currently priced at $44.12, has shown volatility over the past year. Technical indicators present mixed signals, and the company has underperformed compared to the S&P 500, necessitating careful observation of its market dynamics.